MADISON, Wis., December 11, 2025--(BUSINESS WIRE)--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced the first clinical study results ...

Matthew Fisher is a right-arm fast-medium bowler who plays for Surrey and England Lions. The 28-year-old has been added to England's Test squad for the final three Tests of the Ashes after quick Mark ...

The Arknights: Endfield “Beta Test II” will begin on November 28 at 7:00 p.m. PT / 10:00 p.m. ET for PC, iOS, and Android, and the “PlayStation 5 Technical Test” featuring identical content will begin ...

Abbott is getting into cancer testing with its $21 billion acquisition Exact Sciences, the maker of the game-changing colorectal cancer test Cologuard. Abbott markets well-known diagnostics for ...

Abbott made a takeover offer for Exact Sciences. The two companies want to team up to combat cancer. Under the terms of the deal, Exact Sciences' stockholders would receive $105 per share in cash. The ...

Abbott to buy Exact Sciences in $23 billion deal Exact's flagship colorectal cancer test to join Abbott's portfolio Abbott eyes international expansion for Exact's tests Aims for broad reimbursement ...

Forbes contributors publish independent expert analyses and insights. Bruce Japsen writes about healthcare business and policy. Abbott Laboratories $21 billion deal to acquire cancer test maker Exact ...

North suburban-based Abbott Laboratories announced a $21 billion deal Thursday morning to acquire Exact Sciences, the maker of Cologuard — its largest acquisition in a decade. The deal will allow ...

The pending $23 billion sale of Madison-based Exact Sciences to health care giant Abbott centers on Exact Sciences' flagship product: colorectal cancer test Cologuard. Exact Sciences markets Cologuard ...